先端巨大症(Acromegaly)及び巨人症(Gigantism):疫学的予測(~2023)

◆英語タイトル:EpiCast Report: Acromegaly and Gigantism - Epidemiology Forecast to 2023
◆商品コード:GDHCER070-14
◆発行会社(リサーチ会社):GlobalData
◆発行日:2014年12月1日
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥415,480見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥830,960見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD11,985 ⇒換算¥1,246,440見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

EpiCast Report: Acromegaly and Gigantism – Epidemiology Forecast to 2023

Summary

Acromegaly and gigantism are rare disorders of the pituitary gland characterized by the hypersecretion of growth hormone (GH). GH excess beginning in adulthood is known as acromegaly, whereas GH excess beginning during childhood is known as gigantism.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of acromegaly in the 6MM from 25,354 diagnosed prevalent cases in 2013 to 26,884 diagnosed prevalent cases in 2023, at an Annual Growth Rate (AGR) of 0.60% in the forecast period. Similarly, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of gigantism in the 6MM from 591 diagnosed prevalent cases in 2013 to 621 diagnosed prevalent cases in 2023, at an AGR of 0.51% in the forecast period. The 6MM had an estimated 22,408 diagnosed prevalent cases of acromegaly and gigantism receiving any surgical treatment in 2013, and the number of diagnosed prevalent cases of acromegaly and gigantism receiving any surgical treatment is expected to increase to 23,765 by 2023, at an AGR of 0.61%.

GlobalData epidemiologists utilized comprehensive, country-specific data from national acromegaly registers and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed prevalent cases of acromegaly, as well as the diagnosed prevalent cases of gigantism. For all the 6MM, acromegaly and gigantism cases were segmented by age and sex, and then further segmented into the type of pituitary adenoma, and the need for surgical intervention. Additionally, the cases of acromegaly and gigantism used in this forecast fulfilled the most commonly used diagnostic criteria across the globe, which are based on GH and IGF-1 levels. Finally, the same forecast methodology was used across the 6MM, thereby allowing for meaningful global comparisons of the diagnosed prevalent cases of acromegaly, and the diagnosed prevalent cases of gigantism across these markets.

Scope

- The Acromegaly and Gigantism EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for acromegaly and gigantism in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acromegaly and gigantism, segmented by sex, age (in 15-year age groups beginning at 15 years and ending at ≥75 years in acromegaly cases, and beginning at 0 years and ending at ≥75 years in gigantism cases), type of pituitary adenoma (macroadenoma or microadenoma), and whether any surgical intervention was received in these markets.
- The acromegaly and gigantism epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

The acromegaly and gigantism EpiCast series will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global acromegaly and gigantism market.
- Quantify patient populations in the global acromegaly and gigantism market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for acromegaly and gigantism therapeutics in each of the markets covered.

【レポートの目次】

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 12
3.4 Forecast Methodology 13
3.4.1 Sources Used 14
3.4.2 Sources Not Used 19
3.4.3 Forecast Assumptions and Methods 21
3.5 Epidemiological Forecast for Acromegaly (2013-2023) 32
3.5.1 Diagnosed Prevalent Cases of Acromegaly 32
3.5.2 Age-Specific Diagnosed Prevalent Cases of Acromegaly 33
3.5.3 Sex-Specific Diagnosed Prevalent Cases of Acromegaly 35
3.5.4 Age-Standardized Diagnosed Prevalence of Acromegaly 36
3.6 Epidemiological Forecast for Gigantism (2013-2023) 37
3.6.1 Diagnosed Prevalent Cases of Gigantism 37
3.6.2 Age-Specific Diagnosed Prevalent Cases of Gigantism 39
3.6.3 Sex-Specific Diagnosed Prevalent Cases of Gigantism 40
3.6.4 Age-Standardized Diagnosed Prevalence of Gigantism 42
3.7 Epidemiological Forecast for Acromegaly and Gigantism with Macroadenomas, Microadenomas, and Cases Receiving Any Surgical Treatment (2013-2023) 43
3.7.1 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Macroadenomas 43
3.7.2 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Microadenomas 44
3.7.3 Diagnosed Prevalent Cases of Acromegaly and Gigantism Receiving Any Surgical Treatment 45
3.8 Discussion 46
3.8.1 Epidemiological Forecast Insight 46
3.8.2 Limitations of the Analysis 47
3.8.3 Strengths of the Analysis 47
4 Appendix 49
4.1 Bibliography 49
4.2 About the Authors 53
4.2.1 Epidemiologists 53
4.2.2 Reviewers 53
4.2.3 Acting Director of Epidemiology 54
4.2.4 Global Head of Healthcare 55
4.3 About GlobalData 56
4.4 About EpiCast 56
4.5 Disclaimer 57

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Acromegaly and Gigantism 11
Table 2: Summary of the Global Reported Cases and Estimated Prevalence of Acromegaly 13
Table 3: Global Consensus Criteria for the Diagnosis and Cure of Acromegaly 14
Table 4: Sources of Acromegaly and Gigantism Prevalence Data in the 6MM 14
Table 5: Sources of Macroadenoma, Microadenoma, and Surgery Data in the 6MM 15
Table 6: 6MM, Diagnosed Prevalent Cases of Acromegaly, Both Sexes, Ages ≥15 Years, N, 2013-2023 32
Table 7: 6MM, Age-Specific Diagnosed Prevalent Cases of Acromegaly, Both Sexes, N (Row %), 2013 34
Table 8: 6MM, Sex-Specific Diagnosed Prevalent Cases of Acromegaly, Ages ≥15 Years, N (Row %), 2013 35
Table 9: 6MM, Diagnosed Prevalent Cases of Gigantism, Both Sexes, All Ages, N, 2013-2023 38
Table 10: 6MM, Age-Specific Diagnosed Prevalent Cases of Gigantism, Both Sexes, N (Row %), 2013 39
Table 11: 6MM, Sex-Specific Diagnosed Prevalent Cases of Gigantism, All Ages, N (Row %), 2013 41

1.2 List of Figures
Figure 1: 6MM, Diagnosed Prevalent Cases of Acromegaly, Both Sexes, Ages ≥15 Years, N, 2013-2023 33
Figure 2: 6MM, Age-Specific Diagnosed Prevalent Cases of Acromegaly, Both Sexes, Ages ≥15 Years, N, 2013 34
Figure 3: 6MM, Sex-Specific Diagnosed Prevalent Cases of Acromegaly, Ages ≥15 Years, N, 2013 36
Figure 4: 6MM, Age-Standardized Diagnosed Prevalence of Acromegaly (Cases per Million Population), Ages ≥15 Years, by Sex, 2013 37
Figure 5: 6MM, Diagnosed Prevalent Cases of Gigantism, Both Sexes, All Ages, N, 2013-2023 38
Figure 6: 6MM, Age-Specific Diagnosed Prevalent Cases of Gigantism, Both Sexes, All Ages, N, 2013 40
Figure 7: 6MM, Sex-Specific Diagnosed Prevalent Cases of Gigantism, All Ages, N, 2013 41
Figure 8: 6MM, Age-Standardized Diagnosed Prevalence of Gigantism (Cases per Million Population), All Ages, by Sex, 2013 42
Figure 9: 6MM, Diagnosed Prevalent Cases of Acromegaly (Ages ≥15 Years) and Gigantism (All Ages) with Macroadenomas, Both Sexes, N, 2013 and 2023 43
Figure 10: 6MM, Diagnosed Prevalent Cases of Acromegaly (Ages ≥15 Years) and Gigantism (All Ages) with Microadenomas, Both Sexes, N, 2013 and 2023 44
Figure 11: 6MM, Diagnosed Prevalent Cases of Acromegaly (Ages ≥15 Years) and Gigantism (All Ages) Receiving Any Surgical Treatment, Both Sexes, N, 2013 and 2023 45

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[先端巨大症(Acromegaly)及び巨人症(Gigantism):疫学的予測(~2023)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆